Fully agree....and why I’m invested here. The difference between 50% royalty (or whatever rate you can get from BP) is that CytoDyn will never become a BP. This path makes sense in many ways, but given the potential of leronlimab it could potentially make the transition to a permanent player or BP........but would need all the missing pieces like R&D, commercialization, etc.....it’s a really far stretch from our 10 employees or so to get there or even consider it at this point.
IMO this is the most unfortunate part of the RP fallout. He had the research knowledge and connections that could’ve made this outcome much more likely with the right intentions.
Either way, I feel current shareholders have a really bright future. It’ll be a cool story to talk about in 10 years IMO!!
(0)
(0)
CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.